Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1966 2
1967 1
1968 3
1969 3
1970 2
1971 3
1972 1
1974 2
1975 2
1976 2
1977 1
1980 6
1982 1
1983 2
1984 3
1985 3
1986 3
1987 1
1988 4
1989 4
1990 1
1991 2
1992 3
1993 1
1994 4
1996 2
1997 1
1998 1
1999 3
2000 5
2001 3
2002 4
2003 1
2004 1
2005 5
2006 1
2008 1
2009 4
2010 4
2011 4
2013 1
2014 2
2015 2
2016 3
2019 6
2020 1
2021 1
2022 1
2023 2
2024 5
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Cazzola M, et al. Eur Respir Rev. 2015 Sep;24(137):451-61. doi: 10.1183/16000617.00002215. Eur Respir Rev. 2015. PMID: 26324807 Free PMC article. Review.
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out a meta-analysis testing the available evidence that NAC tr …
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis …
N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
Papi A, Alfano F, Bigoni T, Mancini L, Mawass A, Baraldi F, Aljama C, Contoli M, Miravitlles M. Papi A, et al. Arch Bronconeumol. 2024 May;60(5):269-278. doi: 10.1016/j.arbres.2024.03.010. Epub 2024 Mar 18. Arch Bronconeumol. 2024. PMID: 38555190 Free article. English, Spanish.
INTRODUCTION: N-acetylcysteine (NAC) is a mucolytic agent with antioxidant properties. Oxidative stress is a key pathogenic mechanism in chronic respiratory conditions such as COPD and chronic bronchitis (CB). ...
INTRODUCTION: N-acetylcysteine (NAC) is a mucolytic agent with antioxidant properties. Oxidative stress is a key pathogenic me …
Effect of Orally Administered N-Acetylcysteine on Chronic Bronchitis: A Meta-analysis.
Wei J, Pang CS, Han J, Yan H. Wei J, et al. Adv Ther. 2019 Dec;36(12):3356-3367. doi: 10.1007/s12325-019-01111-4. Epub 2019 Oct 9. Adv Ther. 2019. PMID: 31598901
INTRODUCTION: The effect of N-acetylcysteine (NAC) treatment for patients with chronic bronchitis (CB) is controversial. ...
INTRODUCTION: The effect of N-acetylcysteine (NAC) treatment for patients with chronic bronchitis (CB) is contro …
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P, Sathananthan K, Fortescue R. Poole P, et al. Cochrane Database Syst Rev. 2019 May 20;5(5):CD001287. doi: 10.1002/14651858.CD001287.pub6. Cochrane Database Syst Rev. 2019. PMID: 31107966 Free PMC article.
BACKGROUND: Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD) may suffer recurrent exacerbations with an increase in volume or purulence of sputum, or both. ...SELECTION CRITERIA: We included randomised studies that compared …
BACKGROUND: Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD) may suffer recurrent ex …
The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. Stey C, et al. Eur Respir J. 2000 Aug;16(2):253-62. doi: 10.1034/j.1399-3003.2000.16b12.x. Eur Respir J. 2000. PMID: 10968500 Free article.
The role of N-acetylcysteine (NAC) in the treatment of chronic bronchitis is unclear. Since a number of studies have been published on this topic, a systematic review of published studies seems justified. ...Whether this benefit is sufficient to justif …
The role of N-acetylcysteine (NAC) in the treatment of chronic bronchitis is unclear. Since a number of studies …
Efficacy and Safety of N-Acetylcysteine for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
Zhang L, Xiong Y, Du L. Zhang L, et al. Biomed Res Int. 2022 Jun 26;2022:9133777. doi: 10.1155/2022/9133777. eCollection 2022. Biomed Res Int. 2022. Retraction in: Biomed Res Int. 2023 Nov 29;2023:9816263. doi: 10.1155/2023/9816263. PMID: 35795313 Free PMC article. Retracted. Clinical Trial.
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis are associated with poor clinical outcomes. ...High-dose NAC has no marked clinical benefits for COPD patients with concurrent chronic bronchitis....
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis are associated with poor …
Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review.
Calverley P, Rogliani P, Papi A. Calverley P, et al. Drug Saf. 2021 Mar;44(3):273-290. doi: 10.1007/s40264-020-01026-y. Epub 2020 Dec 16. Drug Saf. 2021. PMID: 33326056 Free PMC article. Review.
N-Acetylcysteine (NAC) is widely used in respiratory medicine, with a maximum licensed dose in chronic use of 600 mg/day; however, some clinical trials have studied the efficacy of NAC at higher doses. ...Most of the studies used oral NAC and were conducted o …
N-Acetylcysteine (NAC) is widely used in respiratory medicine, with a maximum licensed dose in chronic use of 600 mg/da …
Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Ohnishi H, Tanimoto T, Inaba R, Eitoku M. Ohnishi H, et al. Respir Investig. 2024 Nov;62(6):1168-1175. doi: 10.1016/j.resinv.2024.10.004. Epub 2024 Oct 15. Respir Investig. 2024. PMID: 39413571
BACKGROUND: The efficacy and safety of mucolytics in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis or exacerbations of COPD have been reported. ...METHODS: Reports from randomized controlled trials to evaluate the efficacy …
BACKGROUND: The efficacy and safety of mucolytics in patients with chronic obstructive pulmonary disease (COPD) and chronic …
127 results